The latest domestic price information and purchase methods of Pralsetinib in 2025

Pralsetinib (trade name GAVRETO®) is a targeted drug targeting RET fusion-positive tumors. In 2021 it has been approved by the State Food and Drug Administration for marketing in China for the treatment of patients with non-small cell lung cancer and thyroid cancer. As of 2025 , the drug has not yet entered the national medical insurance catalog, so patients still need to pay the full amount out of pocket when purchasing it. Because it is positioned as a precision treatment drug, the user population is relatively small, and the market price has always been maintained at a high level.

Currently in the Chinese market, the common specifications of the original drug Platinib are 100mg60 tablets and 100mg120 tablets. The price range fluctuates widely. 100mg*120 A box of capsules usually costs more than 20,000 yuan, but in some areas it even sells for around 60,000 yuan. Compared with similar imported targeted drugs, the price of platinib is not advantageous, which imposes a greater financial burden on patients for long-term medication. It is also one of the biggest concerns for patients when it is not covered by medical insurance.

In overseas markets, the price of platinib’s original drug is higher, 60 The price of a capsule is between RMB 40,000 and RMB 100,000, which varies greatly depending on the region and channel. However, some countries have developed and produced generic drugs of Platinib, among which the generic drugs produced in Laos have attracted the most attention. The Lao version 100mg*120 The price of the tablets is only more than 3,000 yuan, which is several times cheaper than the original drug, providing patients with a more feasible alternative.

In China, if patients need to use platinib, they can purchase the original drug through regular hospitals and DTP pharmacies to ensure the safety and reliability of the source of the drug. For patients with a heavy financial burden, they can consider obtaining overseas generic drugs through regular cross-border pharmacy channels, but they must be wary of counterfeit and substandard drugs to avoid affecting the treatment effect due to unknown drug sources. With the gradual advancement of domestic localized production and the possible progress of negotiations on the future medical insurance catalog, the price of platinib may further decline. Patients can also pay attention to patient assistance projects or clinical trials to obtain more medication support.

Reference link:https://www.drugs.com